Sodium diethyldithiocarbamate,98%  (Synonyms: Ditiocarb sodium,98%)

Sodium diethyldithiocarbamate,98% (Ditiocarb sodium,98%) is a copper reagent. The reaction with Cu²⁺ solution resulted in the formation of a complex, which increased the copper displacement precipitation rate. Sodium diethyldithiocarbamate can reduce HIV infection and can be used in adjuvant immune research of high-risk breast cancer^[1][2][3].

Sodium diethyldithiocarbamate,98% reacts with the Cu²⁺ solution giving a complex of copper diethyldithiocarbamate, which enhances the rate of cementation^[1]. Sodium diethyldithiocarbamate,98% is an agent with strong antioxidant capacity and chelating activities^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sodium diethyldithiocarbamate,98% improves the depressed immune responses of newborn and aged mice. Sodium diethyldithiocarbamate,98% prevents cisplatin nephrotoxicity in animals without reducing the antitumor activity. In that AIDS model, Sodium diethyldithiocarbamate,98% reduces lymphadenopathy and hypergammaglobulinemia, restores immunocompetence, and prolongs survival^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

171.26

C₅H₁₀NNaS₂

148-18-5

Solid

White to light brown

S=C(S[Na])N(CC)CC

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293.

  [2]. Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538-44.  [Content Brief]

  [3]. Dufour P, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6(1):9-12.  [Content Brief]